SUPERNUS PHARMACEUTICALS, INC. Capital Expenditures Incurred but Not yet Paid
SUPERNUS PHARMACEUTICALS, INC. (SUPN) reported Capital Expenditures Incurred but Not yet Paid of $0 for the 9-month period ending 2023-09-30, per its 10-Q filed 2023-11-08.
Discontinued › Cash Flow › Other Cash Flow Items
us-gaap:CapitalExpendituresIncurredButNotYetPaid · last filed 2023-11-08
- SUPERNUS PHARMACEUTICALS, INC. capital expenditures incurred but not yet paid for the quarter ending 2023-09-30 was $0.00.
- SUPERNUS PHARMACEUTICALS, INC. capital expenditures incurred but not yet paid for the quarter ending 2023-06-30 was $0.00, a 100.00% decline year-over-year.
- SUPERNUS PHARMACEUTICALS, INC. capital expenditures incurred but not yet paid for the quarter ending 2023-03-31 was $0.00, a 100.00% decline year-over-year.
- SUPERNUS PHARMACEUTICALS, INC. capital expenditures incurred but not yet paid for the quarter ending 2022-09-30 was $0.00.
| Period end | Capital Expenditures Incurred but Not yet Paid 3 month | Capital Expenditures Incurred but Not yet Paid 6 month | Capital Expenditures Incurred but Not yet Paid 9 month |
|---|---|---|---|
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | $0.00 derived: sum of 2 quarters · filed 2023-11-08 | $0.00 10-Q · filed 2023-11-08 |
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $0.00 10-Q · filed 2023-08-08 | |
| 2023-03-31 | $0.00 10-Q · filed 2023-05-09 | ||
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | $31.00K derived: sum of 2 quarters · filed 2023-11-08 | $580.00K 10-Q · filed 2023-11-08 |
| 2022-06-30 | $31.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $580.00K 10-Q · filed 2023-08-08 | |
| 2022-03-31 | $549.00K 10-Q · filed 2023-05-09 | ||
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | $0.00 derived: sum of 2 quarters · filed 2022-11-09 | $0.00 10-Q · filed 2022-11-09 |
| 2021-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | $0.00 10-Q · filed 2022-08-08 | |
| 2021-03-31 | $0.00 10-Q · filed 2022-05-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |